KR20240004602A - 포스포라미다이트 없이 핵산을 효소 합성하기 위한 조성물 및 방법 - Google Patents
포스포라미다이트 없이 핵산을 효소 합성하기 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20240004602A KR20240004602A KR1020237040428A KR20237040428A KR20240004602A KR 20240004602 A KR20240004602 A KR 20240004602A KR 1020237040428 A KR1020237040428 A KR 1020237040428A KR 20237040428 A KR20237040428 A KR 20237040428A KR 20240004602 A KR20240004602 A KR 20240004602A
- Authority
- KR
- South Korea
- Prior art keywords
- sequence
- iisre
- addamer
- nucleic acid
- adamer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 163
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 120
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 120
- 238000000034 method Methods 0.000 title claims abstract description 108
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 238000003786 synthesis reaction Methods 0.000 title abstract description 16
- 150000008300 phosphoramidites Chemical class 0.000 title abstract description 10
- 230000015572 biosynthetic process Effects 0.000 title description 13
- 230000002255 enzymatic effect Effects 0.000 title description 2
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 7
- 108020004414 DNA Proteins 0.000 claims description 156
- 239000007787 solid Substances 0.000 claims description 126
- 239000002773 nucleotide Substances 0.000 claims description 76
- 125000003729 nucleotide group Chemical group 0.000 claims description 75
- 102000004190 Enzymes Human genes 0.000 claims description 53
- 108090000790 Enzymes Proteins 0.000 claims description 53
- 229940088598 enzyme Drugs 0.000 claims description 53
- 102000003960 Ligases Human genes 0.000 claims description 43
- 108090000364 Ligases Proteins 0.000 claims description 43
- 108091008146 restriction endonucleases Proteins 0.000 claims description 43
- 108091023037 Aptamer Proteins 0.000 claims description 41
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 36
- 206010019133 Hangover Diseases 0.000 claims description 35
- 108060002716 Exonuclease Proteins 0.000 claims description 34
- 102000013165 exonuclease Human genes 0.000 claims description 34
- 241001515965 unidentified phage Species 0.000 claims description 33
- 102000053602 DNA Human genes 0.000 claims description 31
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 28
- 239000013612 plasmid Substances 0.000 claims description 24
- 230000000295 complement effect Effects 0.000 claims description 22
- 238000010367 cloning Methods 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 230000003100 immobilizing effect Effects 0.000 claims description 13
- 239000011324 bead Substances 0.000 claims description 12
- 239000003446 ligand Substances 0.000 claims description 9
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 8
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 8
- 102000010645 MutS Proteins Human genes 0.000 claims description 6
- 108010038272 MutS Proteins Proteins 0.000 claims description 6
- 108010061982 DNA Ligases Proteins 0.000 claims description 5
- 102000012410 DNA Ligases Human genes 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 229920002223 polystyrene Polymers 0.000 claims description 5
- 101000927847 Homo sapiens DNA ligase 3 Proteins 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 230000001902 propagating effect Effects 0.000 claims description 3
- 108090000190 Thrombin Proteins 0.000 claims description 2
- 229960004072 thrombin Drugs 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 3
- 230000001404 mediated effect Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 145
- 239000013638 trimer Substances 0.000 description 25
- 238000003776 cleavage reaction Methods 0.000 description 22
- 238000013461 design Methods 0.000 description 21
- 230000007017 scission Effects 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 15
- 230000000670 limiting effect Effects 0.000 description 15
- 239000000370 acceptor Substances 0.000 description 12
- 230000029087 digestion Effects 0.000 description 12
- 238000010586 diagram Methods 0.000 description 11
- 238000001668 nucleic acid synthesis Methods 0.000 description 11
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 8
- 241000701959 Escherichia virus Lambda Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 108010055863 gene b exonuclease Proteins 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 229940113082 thymine Drugs 0.000 description 4
- 238000001261 affinity purification Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000002515 oligonucleotide synthesis Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108010040614 terminase Proteins 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 108010093096 Immobilized Enzymes Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 239000010815 organic waste Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- GOMLCFUVZKLQCO-HTLAMOOLSA-N thrombin aptamer Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)[C@@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 GOMLCFUVZKLQCO-HTLAMOOLSA-N 0.000 description 2
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 108091027757 Deoxyribozyme Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000010891 toxic waste Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y605/00—Ligases forming phosphoric ester bonds (6.5)
- C12Y605/01—Ligases forming phosphoric ester bonds (6.5) forming phosphoric ester bonds (6.5.1)
- C12Y605/01001—DNA ligase (ATP) (6.5.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Luminescent Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179828P | 2021-04-26 | 2021-04-26 | |
| US63/179,828 | 2021-04-26 | ||
| PCT/US2022/026333 WO2022232134A1 (en) | 2021-04-26 | 2022-04-26 | Compositions and methods for phosphoramedite-free enzymatic synthesis of nucleic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240004602A true KR20240004602A (ko) | 2024-01-11 |
Family
ID=81854492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237040428A Pending KR20240004602A (ko) | 2021-04-26 | 2022-04-26 | 포스포라미다이트 없이 핵산을 효소 합성하기 위한 조성물 및 방법 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240209407A1 (https=) |
| EP (1) | EP4330388A1 (https=) |
| JP (1) | JP2024517998A (https=) |
| KR (1) | KR20240004602A (https=) |
| CN (1) | CN117597441A (https=) |
| AU (1) | AU2022267235A1 (https=) |
| CA (1) | CA3216430A1 (https=) |
| WO (1) | WO2022232134A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025120370A1 (en) * | 2023-12-08 | 2025-06-12 | Camena Bioscience Limited | Compositions and methods for solution-phase, phosphoramidite-free synthesis of nucleic acids |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19925862A1 (de) * | 1999-06-07 | 2000-12-14 | Diavir Gmbh | Verfahren zur Synthese von DNA-Fragmenten |
| AU2002225234A1 (en) * | 2001-01-29 | 2002-08-12 | Isis Innovation Limited | Streptavidin aptamere |
| ES2310197T3 (es) * | 2002-10-18 | 2009-01-01 | Sloning Biotechnology Gmbh | Metodo para la preparacion de moleculas de acido nucleico. |
| US9115352B2 (en) * | 2008-03-31 | 2015-08-25 | Sloning Biotechnology Gmbh | Method for the preparation of a nucleic acid library |
| ES2909073T3 (es) | 2016-09-21 | 2022-05-05 | Univ Muenchen Tech | Producción biotecnológica escalable de moléculas de adn monocatenario de secuencia y longitud definidas |
| US11560565B2 (en) * | 2018-06-13 | 2023-01-24 | Auburn University | Electrochemical detection nanostructure, systems, and uses thereof |
-
2022
- 2022-04-26 EP EP22726858.8A patent/EP4330388A1/en active Pending
- 2022-04-26 JP JP2024508996A patent/JP2024517998A/ja active Pending
- 2022-04-26 WO PCT/US2022/026333 patent/WO2022232134A1/en not_active Ceased
- 2022-04-26 CN CN202280045158.3A patent/CN117597441A/zh active Pending
- 2022-04-26 AU AU2022267235A patent/AU2022267235A1/en not_active Abandoned
- 2022-04-26 CA CA3216430A patent/CA3216430A1/en active Pending
- 2022-04-26 US US18/556,773 patent/US20240209407A1/en active Pending
- 2022-04-26 KR KR1020237040428A patent/KR20240004602A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4330388A1 (en) | 2024-03-06 |
| WO2022232134A1 (en) | 2022-11-03 |
| AU2022267235A9 (en) | 2023-11-16 |
| AU2022267235A1 (en) | 2023-11-09 |
| US20240209407A1 (en) | 2024-06-27 |
| CA3216430A1 (en) | 2022-11-03 |
| JP2024517998A (ja) | 2024-04-23 |
| CN117597441A (zh) | 2024-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11408020B2 (en) | Methods for in vitro joining and combinatorial assembly of nucleic acid molecules | |
| WO2007117039A1 (en) | Method to isolate 5' ends of nucleic acid and its application | |
| JP2019503712A (ja) | 核酸アセンブリのための方法および組成物 | |
| JP2023525880A (ja) | ライゲーションカップルドｐｃｒの方法 | |
| EP4347872B1 (en) | Oligo-modified nucleotide analogues for nucleic acid preparation | |
| CN108026525A (zh) | 多核苷酸组装的组合物和方法 | |
| KR20240004602A (ko) | 포스포라미다이트 없이 핵산을 효소 합성하기 위한 조성물 및 방법 | |
| EP3559268A1 (en) | Methods and reagents for molecular barcoding | |
| KR20240005893A (ko) | 올리고뉴클레오티드 풀로부터 유전자의 조립 | |
| CN114774411B (zh) | 大片段dna环化连接方法 | |
| EP4392554A1 (en) | Method for generating double-stranded nucleic acid | |
| EP4526443A1 (en) | Preparation of size-controlled nucleic acid fragments | |
| WO2018138218A1 (en) | Gene synthesis using templated chemical ligation | |
| HK1240286B (zh) | 一种核酸的双接头单链环状文库的构建方法和试剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231123 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250423 Comment text: Request for Examination of Application |